RxDoctor Payments Data

William Huffman, MD

Internal Medicine · Moultrie, GANPI 1518149756

Payments from drug & device makers

$8,753in general payments, 2019–2025

Across 538 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Johnson & Johnson$782
  • Boehringer Ingelheim$753
  • Dexcom, Inc.$686
  • Amgen$584
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$8,66299%
  • Education$110%
  • Gifts$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,753 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$464,407
Medicare patients
1,293
Services billed
15,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin176$205,310
EliquisApixaban234$194,902
OzempicSemaglutide174$191,218
TradjentaLinagliptin153$153,275
FarxigaDapagliflozin Propanediol126$134,947
JanuviaSitagliptin Phosphate107$120,397
MounjaroTirzepatide100$106,247
RybelsusSemaglutide46$81,070
KerendiaFinerenone67$71,806
XareltoRivaroxaban66$62,195
TrulicityDulaglutide44$57,323
Diclofenac Sodium75$53,898
LinzessLinaclotide59$35,493
TrintellixVortioxetine Hydrobromide48$31,998
Repatha SureclickEvolocumab51$31,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Combivent Respimat$753$395,347382 claims
Novo NordiskOzempic, Rybelsus$1,172$272,287220 claims
PfizerEliquis$438$194,902234 claims
Lilly USA, LLCMounjaro, Trulicity$413$163,570144 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,117$144,792141 claims
MerckJanuvia$192$120,397107 claims
BayerKerendia$263$71,80667 claims
Johnson & JohnsonXarelto$782$62,19566 claims
AbbVieLinzess$269$35,49359 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$287$31,99848 claims
NovartisEntresto$226$21,07130 claims
Astellas Pharma US IncMyrbetriq$26$12,28711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Moultrie

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →